Effects of Tangshen 1st Capsule on levels of serum SREBP-1c and SREBP-2c and expression of IRS-1, PI3K, and podocin proteins in diabetic nephropathy rats / 中草药

ABSTRACT

Objective To observe effect and possible mechanism of Tangshen 1st Capsule on diabetic nephropathy rats. Methods Diabetic nephropathy model was established by SD rat ip injected with STZ. Dividing model rats randomly into six groups, 15 rats in model group, 15 rats in benazepril (1.04 g/kg) group, 15 rats in Tangshen 1st Capsule (9 g/kg), 15 rats in Tangshen 1st Capsule (6 g/kg), and 15 rats in Tangshen 1st Capsule (3 g/kg) group; In addition, there were 15 rats designated as normal control group. Rats in normal control group and model group were given corresponding drugs for 8 weeks. After 8 weeks, it was time to observe the blood glucose, blood lipid, cystain c, SREBP-1c, SREBP-2c, urinary albumin, expression of IRS-1, PI3K, and podocin protein levels in renal tissue. Results Compared with model group after treatment, in Tangshen 1st Capsule high-dose group and mid-dose group, blood glucose, blood lipid, cystain C, and urinary microalbumin decreased significantly (P 0.05), in high-dose group, and mid-dose group were statistically significant (P < 0.05). Conclusion Tangshen 1st Capsule have protective effects on diabetic nephropathy rats, and its mechanisms are in part associated with reducing blood glucose and blood lipid, and increasing podocin protein expression.